Guidelines for Writing Outcome
Healthcare Associated Infections II: Preventive Measures
Methods of Documentation VI: Case Management Model
Pharmacovigilance
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Standards of Care II
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Apr 20, 2026

Development and Implementation of a Multi-Disciplinary Technology Enhanced Care Pathway for Youth and Adults with Concussion
Published on: January 20, 2019
Daniel L Villeneuve1, Doug Crump2, Natàlia Garcia-Reyero2
1*US EPA Mid-Continent Ecology Division, 6201 Congdon Blvd, Duluth, MN 55804, Environment Canada, Ecotoxicology and Wildlife Health Division, Ottawa, Ontario, Canada K1A 0H3, Institute for Genomics, Biocomputing and Biotechnology, Mississippi State University, Starkville, MS 39762, School of the Environment and Sustainability and Toxicology Centre, University of Saskatchewan, Saskatoon, Saskatchewan, Canada SK S7N 5B3, School of Biological Sciences, University of Plymouth, Plymouth, Devon, PL4 8AA, UK, Water Resources Center, University of Minnesota, St. Paul, MN 55108, European Commission, Joint Research Centre, Via E. Fermi 2749, 21027 Ispra, Italy, Department of Biology and Biochemistry, University of Houston, Houston, TX 77004, Zebrafishlab, Veterinary Physiology and Biochemistry, Department of Veterinary Sciences, University of Antwerp, Universiteitsplein 1, 2610 Wilrijk, Belgium villeneuve.dan@epa.gov.
Formalizing adverse outcome pathway (AOP) development with clear guidance enhances mechanistic toxicology data use in risk assessment. Best practices promote AOP reusability and network connectivity for reliable decision-making.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: